Vistagen Therapeutics reported constructive FDA feedback on its Phase 3 development plan for fasedienol, a treatment for social anxiety disorder (SAD). The FDA supported using the Liebowitz Social Anxiety Scale as the primary endpoint and recognized fasedienol's safety and potential benefits. Vistagen plans to focus on overall treatment of SAD, supported by positive preliminary data from ongoing studies. The company also reported reduced R&D expenses and a net loss of $10.7 million for Q2 FY2027, with cash sufficient to fund operations into 2027 but limited beyond that.
Vistagen's fiscal year 2027 second quarter results provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 14, 2026 04:11 WIB: Among 150 priced health-sector US stocks, 71 rose and 75 fell. Notable movers include AVAH at USD 11.48 with a 1-day change of -6.17% and Pluang order activity showing 97% Buy, DNA at USD 9.62 down 5.96% with 93% Sell activity, and SMMT at USD 14.20 down 5.80% with 88% Buy activity. Typical hold times range from 9 to 19 days.
ArrowMark Financial Corp. announced a monthly cash distribution of $0.15 per share for November 2026, payable on November 30 to shareholders of record as of November 23. This distribution reflects the company's ongoing commitment to provide current i...
Liberty Defense Holdings clarified details of its credit facility and term loan with Parabilis, originally announced in 2024. The company’s subsidiary received a $1.8 million term loan and a $2.5 million revolving credit facility, both secured by sub...
Stardust Power announced a $2.8 million net loss for Q3 2026, an improvement from $4.5 million last year, driven by lower administrative costs and warrant value changes. The company is progressing its lithium refinery project in Muskogee, Oklahoma, d...
byNordic Acquisition Corporation, a special purpose acquisition company, has extended its deadline to complete a business combination by one month, moving it from November 12, 2026, to December 12, 2026. This is the fourth of up to twelve possible on...
Texas Pacific Land Corporation reported a high Return on Invested Capital (ROIC) of 30.81%, significantly surpassing its Weighted Average Cost of Capital (WACC) of 7.73%. This strong performance results in the highest ROIC-to-WACC ratio of 3.98 among...
